A review of current therapies used in the treatment of congestive heart failure
- PMID: 23980607
- DOI: 10.1586/14779072.2013.816478
A review of current therapies used in the treatment of congestive heart failure
Abstract
Congestive heart failure is the leading cause of hospitalizations for patients older than 65 years. There are almost 700,000 new cases of heart failure annually and re-hospitalization rates are as high as 50% within the first few months of initial discharge. These statistics translate to healthcare costs that nearly reached US$40 billion in 2010. Understanding the therapeutic agents that can not only help decrease mortality and morbidity but also decrease the rate of re-hospitalizations is vital in the management of congestive heart failure. Here, the authors highlight the various classes of drugs used in the treatment of heart failure. They then provide a focused review examining the multiple clinical trials that have emphasized the evaluation of mortality, morbidity and hospitalization rates in heart failure patients who are receiving the different types of therapeutic agents.
Similar articles
-
[Treatment of chronic systolic heart failure].Dtsch Med Wochenschr. 2013 Aug;138(31-32):1556. doi: 10.1055/s-0032-1330162. Epub 2013 Jul 24. Dtsch Med Wochenschr. 2013. PMID: 23884736 German. No abstract available.
-
Treatment of advanced heart failure.Cardiol Rev. 2000 May-Jun;8(3):148-57. Cardiol Rev. 2000. PMID: 11174888 Review.
-
Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF): rationale and design.Am Heart J. 2004 Jul;148(1):43-51. doi: 10.1016/j.ahj.2004.03.004. Am Heart J. 2004. PMID: 15215791
-
[Management of heart failure].Soins. 2013 Apr;(774):29-34. Soins. 2013. PMID: 23697056 French.
-
Drug therapy of chronic heart failure in the elderly: the current state of clinical-trial evidence.Curr Opin Cardiol. 2006 Jul;21(4):393-9. doi: 10.1097/01.hco.0000231411.15049.20. Curr Opin Cardiol. 2006. PMID: 16755210 Review.
Cited by
-
Functional remodelling of perinuclear mitochondria alters nucleoplasmic Ca2+ signalling in heart failure.Philos Trans R Soc Lond B Biol Sci. 2022 Nov 21;377(1864):20210320. doi: 10.1098/rstb.2021.0320. Epub 2022 Oct 3. Philos Trans R Soc Lond B Biol Sci. 2022. PMID: 36189813 Free PMC article.
-
Cardiac-specific Conditional Knockout of the 18-kDa Mitochondrial Translocator Protein Protects from Pressure Overload Induced Heart Failure.Sci Rep. 2018 Nov 1;8(1):16213. doi: 10.1038/s41598-018-34451-2. Sci Rep. 2018. PMID: 30385779 Free PMC article.
-
A New Cardiac Channelopathy: From Clinical Phenotypes to Molecular Mechanisms Associated With Nav1.5 Gating Pores.Front Cardiovasc Med. 2018 Oct 9;5:139. doi: 10.3389/fcvm.2018.00139. eCollection 2018. Front Cardiovasc Med. 2018. PMID: 30356750 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical